Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients

Veronique Nussenblatt, Mary McLaughlin, Catherine A. Rehm, Richard A. Lempicki, Terry Brann, Jun Yang, Michael Proschan, Helene C. Highbarger, Robin L. Dewar, Tom Imamichi, Chad Koratich, Avidan U. Neumann, Henry Masur, Michael A. Polis, Shyam Kottilil

Research output: Contribution to journalArticle

Abstract

Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 μg/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes (%) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB.

Original languageEnglish (US)
Pages (from-to)1354-1359
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

HIV
Interferons
Therapeutics
Gene Expression
Liver
Oligonucleotide Array Sequence Analysis
DNA Sequence Analysis
Genotype
Inflammation

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. / Nussenblatt, Veronique; McLaughlin, Mary; Rehm, Catherine A.; Lempicki, Richard A.; Brann, Terry; Yang, Jun; Proschan, Michael; Highbarger, Helene C.; Dewar, Robin L.; Imamichi, Tom; Koratich, Chad; Neumann, Avidan U.; Masur, Henry; Polis, Michael A.; Kottilil, Shyam.

In: AIDS Research and Human Retroviruses, Vol. 23, No. 11, 01.11.2007, p. 1354-1359.

Research output: Contribution to journalArticle

Nussenblatt, V, McLaughlin, M, Rehm, CA, Lempicki, RA, Brann, T, Yang, J, Proschan, M, Highbarger, HC, Dewar, RL, Imamichi, T, Koratich, C, Neumann, AU, Masur, H, Polis, MA & Kottilil, S 2007, 'Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients', AIDS Research and Human Retroviruses, vol. 23, no. 11, pp. 1354-1359. https://doi.org/10.1089/aid.2007.0091
Nussenblatt, Veronique ; McLaughlin, Mary ; Rehm, Catherine A. ; Lempicki, Richard A. ; Brann, Terry ; Yang, Jun ; Proschan, Michael ; Highbarger, Helene C. ; Dewar, Robin L. ; Imamichi, Tom ; Koratich, Chad ; Neumann, Avidan U. ; Masur, Henry ; Polis, Michael A. ; Kottilil, Shyam. / Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. In: AIDS Research and Human Retroviruses. 2007 ; Vol. 23, No. 11. pp. 1354-1359.
@article{0f01c0005d7647b5b42af1697c8572bb,
title = "Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients",
abstract = "Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 μg/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes ({\%}) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB.",
author = "Veronique Nussenblatt and Mary McLaughlin and Rehm, {Catherine A.} and Lempicki, {Richard A.} and Terry Brann and Jun Yang and Michael Proschan and Highbarger, {Helene C.} and Dewar, {Robin L.} and Tom Imamichi and Chad Koratich and Neumann, {Avidan U.} and Henry Masur and Polis, {Michael A.} and Shyam Kottilil",
year = "2007",
month = "11",
day = "1",
doi = "10.1089/aid.2007.0091",
language = "English (US)",
volume = "23",
pages = "1354--1359",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients

AU - Nussenblatt, Veronique

AU - McLaughlin, Mary

AU - Rehm, Catherine A.

AU - Lempicki, Richard A.

AU - Brann, Terry

AU - Yang, Jun

AU - Proschan, Michael

AU - Highbarger, Helene C.

AU - Dewar, Robin L.

AU - Imamichi, Tom

AU - Koratich, Chad

AU - Neumann, Avidan U.

AU - Masur, Henry

AU - Polis, Michael A.

AU - Kottilil, Shyam

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 μg/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes (%) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB.

AB - Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 μg/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes (%) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB.

UR - http://www.scopus.com/inward/record.url?scp=38449092863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449092863&partnerID=8YFLogxK

U2 - 10.1089/aid.2007.0091

DO - 10.1089/aid.2007.0091

M3 - Article

C2 - 18184077

AN - SCOPUS:38449092863

VL - 23

SP - 1354

EP - 1359

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -